	US 12,441,784 B2
	Human antibodies to artemin and methods of use thereof
Susan D. Croll, New Paltz, NY (US); Lynn MacDonald, Harrison, NY (US); and Andrew J. Murphy, Croton-on-Hudson, NY (US)
Assigned to REGENERON PHARMACEUTICALS, INC., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Feb. 7, 2024, as Appl. No. 18/435,815.
Application 18/435,815 is a continuation of application No. 17/724,381, filed on Apr. 19, 2022, granted, now 11,926,661.
Claims priority of provisional application 63/177,369, filed on Apr. 20, 2021.
Prior Publication US 2024/0352111 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 39/395 (2006.01); A61P 29/02 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); A61P 29/02 (2018.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

47 Claims

1. A nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain variable region (HCVR) or a polynucleotide sequence that encodes a light chain variable region (LCVR) of a monoclonal antibody or antigen-binding fragment thereof that specifically binds to artemin, wherein the antibody or antigen-binding fragment thereof comprises:

three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) contained within the HCVR sequence set forth in SEQ ID NO: 2, SEQ ID NO: 22, SEQ ID NO: 42 or SEQ ID NO: 62; and

three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within the LCVR sequence set forth in SEQ ID NO: 10, SEQ ID NO: 30, SEQ ID NO: 50 or SEQ ID NO: 70.